NZ719185A - Crystalline forms of therapeutic compounds and uses thereof - Google Patents

Crystalline forms of therapeutic compounds and uses thereof

Info

Publication number
NZ719185A
NZ719185A NZ719185A NZ71918514A NZ719185A NZ 719185 A NZ719185 A NZ 719185A NZ 719185 A NZ719185 A NZ 719185A NZ 71918514 A NZ71918514 A NZ 71918514A NZ 719185 A NZ719185 A NZ 719185A
Authority
NZ
New Zealand
Prior art keywords
crystalline forms
pharmaceutical compositions
particles
therapeutic compounds
yloxy
Prior art date
Application number
NZ719185A
Other languages
English (en)
Inventor
Elizabeth Enlow
Minh Ngoc Nguyen
Winston Z Ong
Original Assignee
Kala Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kala Pharmaceuticals Inc filed Critical Kala Pharmaceuticals Inc
Publication of NZ719185A publication Critical patent/NZ719185A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
NZ719185A 2013-11-01 2014-10-31 Crystalline forms of therapeutic compounds and uses thereof NZ719185A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361898741P 2013-11-01 2013-11-01
US201462039192P 2014-08-19 2014-08-19
US201462039177P 2014-08-19 2014-08-19
PCT/US2014/063444 WO2015066482A1 (en) 2013-11-01 2014-10-31 Crystalline forms of therapeutic compounds and uses thereof

Publications (1)

Publication Number Publication Date
NZ719185A true NZ719185A (en) 2017-11-24

Family

ID=53005200

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ719185A NZ719185A (en) 2013-11-01 2014-10-31 Crystalline forms of therapeutic compounds and uses thereof

Country Status (10)

Country Link
US (6) US9458169B2 (enExample)
EP (1) EP3062618B1 (enExample)
JP (2) JP6426194B2 (enExample)
KR (1) KR20160099084A (enExample)
CN (2) CN106061261B (enExample)
AU (1) AU2014342042B2 (enExample)
CA (1) CA2928658A1 (enExample)
MX (1) MX355330B (enExample)
NZ (1) NZ719185A (enExample)
WO (1) WO2015066482A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9827191B2 (en) * 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US10864219B2 (en) * 2012-05-03 2020-12-15 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US11596599B2 (en) * 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
KR20160099084A (ko) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. 치료 화합물의 결정질 형태 및 그의 용도
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
CA3036336A1 (en) * 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036065A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2018351520A1 (en) * 2017-10-20 2020-05-07 Kala Pharmaceuticals, Inc. RET9 and VEGFR2 inhibitors
KR102923958B1 (ko) * 2017-12-15 2026-02-06 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 엑소좀 관련 유전자 편집을 이용한 암 치료 방법 및 조성물
JP7474702B2 (ja) 2018-03-28 2024-04-25 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム エキソソームから単離されたｄｎａにおけるエピジェネティック変化の同定法
WO2021069711A1 (en) * 2019-10-10 2021-04-15 Myovant Sciences Gmbh Crystalline forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo- 1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'- methoxyurea
IL292837B2 (en) * 2019-12-02 2025-12-01 Academia Sinica Pdia4 inhibitors and use thereof for inhibiting ?-cell pathogenesis and treating diabetes
WO2021191652A1 (en) * 2020-03-21 2021-09-30 Jafari Javid Mihan Composition and methods for prevention and treatment of vascular disorders
KR102491010B1 (ko) * 2021-09-07 2023-01-20 경희대학교 산학협력단 현탁액에서의 물리적 분쇄를 이용한 안정상 결정 제조방법
CN115820545A (zh) * 2022-12-28 2023-03-21 中国农业大学 提高卵母细胞体外成熟率的培养基及其应用
KR20250138207A (ko) 2023-01-18 2025-09-19 나노폼 핀란드 오와이제이 활성 제약 성분의 결정화 방법
CN119097710B (zh) * 2024-09-11 2025-09-02 山东大学齐鲁医院 Ape1抑制剂在制备治疗过敏性鼻炎药物中的应用

Family Cites Families (337)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4996335A (en) 1980-07-10 1991-02-26 Nicholas S. Bodor Soft steroids having anti-inflammatory activity
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4789724A (en) 1986-10-17 1988-12-06 Massachusetts Institute Of Technology Preparation of anhydride copolymers
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
CA1325382C (en) 1988-01-27 1993-12-21 Takahiro Ogawa Locally administrable therapeutic composition for inflammatory disease
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5442039A (en) 1989-07-17 1995-08-15 The Dow Chemical Company Mesogenic polycyanates and thermosets thereof
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5190956A (en) 1990-09-07 1993-03-02 Schering Corporation Certain N-substituted 3-oximino-2,4-dioxoquinolin-2,4-(1H)diones useful for treating viral infections
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
JPH06509576A (ja) 1991-07-29 1994-10-27 ワーナー−ランバート・コンパニー アセチルコリンエステラーゼ阻害剤としてのキナゾリン誘導体
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US6235313B1 (en) 1992-04-24 2001-05-22 Brown University Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US6197346B1 (en) 1992-04-24 2001-03-06 Brown Universtiy Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
AU660852B2 (en) 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
US5364884A (en) 1993-01-21 1994-11-15 Baylor College Of Medicine Arginine compounds as ocular hypotensive agents
US5534259A (en) 1993-07-08 1996-07-09 Liposome Technology, Inc. Polymer compound and coated particle composition
WO1995003356A1 (en) 1993-07-23 1995-02-02 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5540930A (en) 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
CA2180424C (en) 1994-02-14 1999-05-04 Pankaj Modi Drugs, vaccines and hormones in polylactide coated microspheres
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
AU2096895A (en) 1994-03-07 1995-09-25 Sugen, Incorporated Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
GB9406094D0 (en) 1994-03-28 1994-05-18 Univ Nottingham And University Polymer microspheres and a method of production thereof
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5718388A (en) 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
WO1997020578A1 (en) 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
US6046208A (en) 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
US6517860B1 (en) 1996-12-31 2003-02-11 Quadrant Holdings Cambridge, Ltd. Methods and compositions for improved bioavailability of bioactive agents for mucosal delivery
US6106819A (en) 1996-12-31 2000-08-22 Sucher; David F. Methods of treating headache and functional extraocular and intraocular myotendinitis
EP1021414B1 (en) 1997-01-06 2003-06-18 Cerus Corporation Frangible compounds for pathogen inactivation
CA2277801C (en) 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
GB9713980D0 (en) 1997-07-03 1997-09-10 Danbiosyst Uk New conjugates
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
FR2772763B1 (fr) 1997-12-24 2004-01-23 Sod Conseils Rech Applic Nouveaux analogues tetracycliques de camptothecines, leurs procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
US6165509A (en) 1998-09-01 2000-12-26 University Of Washington Pegylated drug complexed with bioadhesive polymer suitable for drug delivery and methods relating thereto
US6288082B1 (en) 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
PL201475B1 (pl) 1998-09-29 2009-04-30 Wyeth Corp Podstawione 3-cyjanochinoliny jako inhibitory białkowych kinaz tyrozynowych
DK1119567T3 (da) 1998-10-08 2005-07-25 Astrazeneca Ab Quinazolinderivater
US6372246B1 (en) 1998-12-16 2002-04-16 Ortho-Mcneil Pharmaceutical, Inc. Polyethylene glycol coating for electrostatic dry deposition of pharmaceuticals
WO2000040203A2 (en) 1999-01-08 2000-07-13 Emisphere Technologies, Inc. Polymeric delivery agents and delivery agent compounds
GB2345486A (en) 1999-01-11 2000-07-12 Glaxo Group Ltd Heteroaromatic protein tyrosine kinase inhibitors
WO2000042026A1 (en) 1999-01-15 2000-07-20 Novo Nordisk A/S Non-peptide glp-1 agonists
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
DE60013773T2 (de) 1999-02-03 2005-11-10 Biosante Pharmaceuticals, Inc. Methoden zur Herstellung von therapeutischen Kalziumphosphat Partikeln
DK1553097T3 (da) * 1999-02-10 2010-12-13 Astrazeneca Ab Quinazolinderivat som angiogeneseinhibitor og mellemprodukter dertil
KR20020068261A (ko) 1999-02-27 2002-08-27 베링거 잉겔하임 파르마 카게 티로신 키나제에 의해 매개되는 신호 변환에 대한 억제효과를 갖는 4-아미노-퀴나졸린 및 퀴놀린 유도체
DE19911509A1 (de) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
GB9910579D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9910580D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US6521618B2 (en) 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
AR035851A1 (es) 2000-03-28 2004-07-21 Wyeth Corp 3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas
AU2001249644A1 (en) 2000-03-30 2001-10-15 The Penn State Research Foundation Novel compounds for enhancing chemotherapy
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
JP2004505964A (ja) 2000-08-09 2004-02-26 アストラゼネカ　アクチボラグ Ｖｅｇｆ阻害活性を有するキノリン誘導体
DE10042059A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
PL211125B1 (pl) 2000-09-11 2012-04-30 Novartis Vaccines & Diagnostic Pochodne chinolinonu jako inhibitory kinazy tyrozynowej, kompozycje je zawierające i ich zastosowanie
FR2814167B1 (fr) 2000-09-15 2002-11-08 Aventis Pharma Sa Preparation de la camptothecine et de ses derives
EP1332134A2 (en) 2000-10-25 2003-08-06 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
AU2000202A (en) 2000-10-31 2002-05-15 Pr Pharmaceuticals Inc Methods and compositions for enhanced delivery of bioactive molecules
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
GB2370839A (en) 2001-01-06 2002-07-10 Benedikt Timmerman Immunogenic complex useful for disease control
US6855720B2 (en) 2001-03-01 2005-02-15 California Pacific Medical Center Nitrogen-based camptothecin derivatives
TWI261055B (en) 2001-03-23 2006-09-01 Bayer Corp Rho-Kinase Inhibitors
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
SE0101675D0 (sv) 2001-05-11 2001-05-11 Astrazeneca Ab Novel composition
DE10128110A1 (de) 2001-06-11 2003-01-02 Univ Hannover Verbindungen zum Anlagern an Nucleinsäuren
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
WO2003000266A1 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinolines and uses thereof
EP1408980A4 (en) 2001-06-21 2004-10-20 Ariad Pharma Inc NEW QUINAZOLINES AND THEIR USE
EP1406593B1 (en) 2001-06-22 2010-08-25 Johns Hopkins University School of Medicine Biodegradable polymer compositions, compositions and uses related thereto
US20050191359A1 (en) 2001-09-28 2005-09-01 Solubest Ltd. Water soluble nanoparticles and method for their production
GB0126433D0 (en) 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
GB0128108D0 (en) 2001-11-23 2002-01-16 Astrazeneca Ab Therapeutic use
CA2468159A1 (en) 2001-11-27 2003-06-05 Merck & Co., Inc. 4-aminoquinoline compounds
US7084156B2 (en) 2001-11-27 2006-08-01 Merck & Co., Inc. 2-Aminoquinoline compounds
AU2002365611A1 (en) 2001-12-05 2003-06-17 F. Hoffmann - La Roche Ag Inflammation modulators
JP4452899B2 (ja) 2001-12-13 2010-04-21 味の素株式会社 新規フェニルアラニン誘導体
WO2003051906A2 (en) 2001-12-14 2003-06-26 Smithkline Beecham Corporation Compounds and methods
DK1474420T3 (da) * 2002-02-01 2012-05-21 Astrazeneca Ab Quinazolinforbindelser
US6822097B1 (en) 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
AU2006220411B2 (en) 2002-03-20 2008-06-26 Alkermes, Inc. Inhalable Sustained Therapeutic Formulations
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
AU2003241898A1 (en) 2002-06-03 2003-12-19 Mitsubishi Pharma Corporation PREVENTIVES AND/OR REMEDIES FOR SUBJECTS WITH THE EXPRESSION OR ACTIVATION OF Her2 AND/OR EGFR
US20050256157A1 (en) 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
BR0313743A (pt) 2002-08-23 2005-07-05 Chiron Corp Benzimidazol quinolinonas e usos destas
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
CA2500218A1 (en) 2002-09-26 2004-04-08 Yamanouchi Pharmaceutical Co., Ltd. Drug absorptivity improving agent
TW200505861A (en) 2002-11-08 2005-02-16 Encysive Pharmaceuticals Inc Combination products with carboxylic acid derivatives that inhibit the binding of integrins to their receptors and other therapeutic compounds
US7488823B2 (en) 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
EP1567506A4 (en) 2002-11-20 2007-06-20 Array Biopharma Inc CYANOGUANIDINES AND CYANOAMIDINES AS INHIBITORS OF ERBB2 AND EGFR
PT1847539E (pt) 2002-12-24 2009-10-06 Astrazeneca Ab Derivados de quinazolina
US7407946B2 (en) 2002-12-24 2008-08-05 Astrazeneca Ab Quinazoline compounds
WO2004058782A1 (en) 2002-12-24 2004-07-15 Astrazeneca Ab Therapeutic quinazoline derivatives
JPWO2004060400A1 (ja) 2003-01-06 2006-05-11 那波　宏之 上皮成長因子受容体を分子標的とする抗精神病薬
US20050266090A1 (en) 2003-04-29 2005-12-01 Ales Prokop Nanoparticular targeting and therapy
US20050058603A1 (en) 2003-05-02 2005-03-17 Case Western Reserve University Drug delivery system based on polymer nanoshells
CA2523035C (en) 2003-05-22 2011-04-26 Elan Pharma International Ltd. Sterilization of dispersions of nanoparticulate active agents with gamma radiation
US7727969B2 (en) 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
US20050009809A1 (en) 2003-07-11 2005-01-13 Matthias Gerlach Acridine derivatives and their use as medicaments
DE10331500A1 (de) 2003-07-11 2005-02-24 Zentaris Gmbh Neue Acridin-Derivate und deren Verwendung als Arzneimittel
US20050124562A1 (en) 2003-09-23 2005-06-09 Joseph Guiles Bis-quinazoline compounds for the treatment of bacterial infections
WO2005035521A1 (en) 2003-10-09 2005-04-21 Argenta Discovery Ltd. Substituted quinolines as mcr modulators
WO2005047244A2 (en) 2003-11-07 2005-05-26 Chiron Corporation Inhibition of fgfr3 and treatment of multiple myeloma
GB0330002D0 (en) * 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
WO2005073224A2 (en) 2004-01-23 2005-08-11 Amgen Inc Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
WO2005070891A2 (en) 2004-01-23 2005-08-04 Amgen Inc Compounds and methods of use
WO2005072710A2 (en) 2004-01-28 2005-08-11 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
SE0400284D0 (sv) 2004-02-10 2004-02-10 Astrazeneca Ab Novel compounds
TW200529846A (en) 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
US7875624B2 (en) 2004-02-20 2011-01-25 Novartis Vaccines And Diagnostics, Inc. Modulating and measuring cellular adhesion
WO2005084710A2 (en) 2004-03-02 2005-09-15 Massachusetts Institute Of Technology Nanocell drug delivery system
JP2007530573A (ja) 2004-03-25 2007-11-01 ボーシュ アンド ローム インコーポレイティド ドライアイの治療にロテプレドノールエタボネートを使用すること
WO2005097134A2 (en) 2004-03-31 2005-10-20 The Scripps Research Institute Quinazoline based protein kinase inhibitors
AU2005244745B2 (en) 2004-04-13 2012-05-03 Synta Pharmaceuticals Corp. Disalt inhibitors of IL-12 production
MXPA06011871A (es) 2004-04-15 2007-10-08 Chiasma Inc Composiciones capaces de facilitar la penetracion a traves de una barrera biologica.
ES2246694B1 (es) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Nanoparticulas pegiladas.
KR20070006889A (ko) 2004-05-03 2007-01-11 노파르티스 아게 Ｓ1ｐ 수용체 작용제 및 ｊａｋ3 키나제 억제제를 포함하는조합물
US20100226931A1 (en) 2004-06-24 2010-09-09 Nicholas Valiante Compounds for immunopotentiation
EP1768692B8 (en) 2004-07-01 2015-06-17 Yale University Targeted and high density drug loaded polymeric materials
EP1768964A1 (en) 2004-07-06 2007-04-04 Angion Biomedica Corporation Quinazoline modulators of hepatocyte growth factor / c-met activity for the treatment of cancer
WO2006030947A1 (ja) 2004-09-13 2006-03-23 Eisai R & D Management Co., Ltd. スルホンアミド含有化合物の血管新生阻害物質との併用
CA2580659C (en) 2004-09-15 2013-02-26 Ivx Animal Health, Inc. Corticosteroid having low systemic absorption
MX2007003506A (es) * 2004-09-27 2007-05-10 Aztrazeneca Ab Terapia de combinacion de cancer que comprende azd2171 e imatinib.
CN101890167B (zh) 2004-10-01 2017-03-01 拉姆斯科股份有限公司 可方便植入的缓释药物组合物
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
TW200616612A (en) 2004-10-08 2006-06-01 Wyeth Corp Method for the teatment of polycystic kidney disease field of invention
EP1802608A1 (en) 2004-10-12 2007-07-04 AstraZeneca AB Quinazoline derivatives for use against cancer
US20060083781A1 (en) 2004-10-14 2006-04-20 Shastri V P Functionalized solid lipid nanoparticles and methods of making and using same
JP2008521900A (ja) 2004-11-30 2008-06-26 アムジエン・インコーポレーテツド キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用
EP1856179B1 (en) 2004-12-10 2013-05-15 Kala Pharmaceuticals, Inc. Functionalized poly (ether-anhydride) block copolymers
MX2007010037A (es) 2005-02-18 2008-02-15 Novartis Vaccines & Diagnostic Agentes antiangiogenicos con aldesleucina.
US9271963B2 (en) 2005-03-03 2016-03-01 Universitat Des Saarlandes Selective inhibitors of human corticosteroid synthases
DE102005009705A1 (de) 2005-03-03 2006-09-07 Universität des Saarlandes Selektive Hemmstoffe humaner Corticoidsynthasen
DE102005011786A1 (de) 2005-03-11 2006-09-14 Pharmasol Gmbh Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen
US8048889B2 (en) 2005-03-29 2011-11-01 Xtl Biopharmaceuticals Ltd. 3,4-disubstituted coumarin and quinolone compounds
AU2006228683B2 (en) 2005-04-01 2012-02-02 Vfp Therapies New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-Alzheimer agents
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
GB0509224D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of intracellular enzymatic activity
GB0509227D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
DK1885336T3 (da) 2005-05-10 2009-05-25 Alcon Inc Suspensionsformuleringer, der omfatter et aktivt princip, et overfladeaktivt poloxamer- eller meroxapolmiddel og en glycol, samt deres anvendelse til fremstilling af et medikament til behandling af öjenlidelser
AU2006247520A1 (en) 2005-05-18 2006-11-23 Wyeth 3-cyanoquinoline inhibitors of TPL2 kinase and methods of making and using the same
MX2007014773A (es) 2005-05-25 2008-02-20 Wyeth Corp Metodo para preparar 3-ciano-quinolinas e intermedios hechos de esta forma.
JP2008545688A (ja) 2005-05-25 2008-12-18 ワイス 置換３−シアノキノリン並びにその中間体を合成する方法
CN1313449C (zh) 2005-07-14 2007-05-02 沈阳中海生物技术开发有限公司 新的喹唑啉类衍生物、含有其的药物组合物以及它们的用途
WO2007015569A1 (ja) 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
FR2889527A1 (fr) 2005-08-05 2007-02-09 Servier Lab Nouveaux composes analogues de la camptothecine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP4792262B2 (ja) 2005-09-09 2011-10-12 富士フイルム株式会社 有機電界発光素子及び錯体化合物
US7732613B2 (en) 2005-09-14 2010-06-08 Bristol-Myers Squibb Company Met kinase inhibitors
WO2007034479A2 (en) 2005-09-20 2007-03-29 Yissum Research Development Company Nanoparticles for targeted delivery of active agents
US7875602B2 (en) 2005-10-21 2011-01-25 Sutter West Bay Hospitals Camptothecin derivatives as chemoradiosensitizing agents
CN1955183B (zh) 2005-10-28 2011-04-20 中国医学科学院药物研究所 20-位酯化的喜树碱衍生物、其制法和其药物组合物与用途
EP1785420A1 (en) 2005-11-14 2007-05-16 4Sc Ag Thiazole analogues and uses thereof
US20070149523A1 (en) 2005-11-14 2007-06-28 Jan Ehlert Thiazole Analogues and Uses Thereof
KR20080089344A (ko) 2005-12-14 2008-10-06 에프. 호프만-라 로슈 아게 Ｃ형 간염 바이러스(ｈｃｖ) 전구약물 제형
US20070149480A1 (en) 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US20070213319A1 (en) 2006-01-11 2007-09-13 Angion Biomedica Corporation Modulators of hepatocyte growth factor/c-Met activity
US20070196860A1 (en) 2006-01-18 2007-08-23 Invitrogen Corporation Methods for Measuring Real Time Kinase Activity
US20070178051A1 (en) 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
WO2008041960A2 (en) 2006-02-24 2008-04-10 Investigen, Inc. Methods and compositions for detecting polynucleotides
WO2007100711A2 (en) 2006-02-24 2007-09-07 Investigen, Inc. Methods and compositions for detecting polynucleotides
WO2007104696A1 (en) 2006-03-15 2007-09-20 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antimalarial agents having polyaromatic structure
GB0605691D0 (en) 2006-03-21 2006-05-03 Novartis Ag Organic Compounds
EP1998809B1 (en) 2006-03-30 2014-06-25 Drais Pharmaceuticals, Inc. Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same
DK2010496T3 (da) 2006-04-14 2010-11-08 Astrazeneca Ab 4-anilinoquinolin-3-carbonsyreamider som CSF-1R-kinaseinhibitorer
CA2651072A1 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
US20100003291A1 (en) 2006-05-15 2010-01-07 Liquidia Technologies, Inc. Nano-particles for cosmetic applications
CA2694955A1 (en) 2006-05-15 2007-11-22 Presidio Pharmaceuticals, Inc. 3,4-disubstituted coumarin and quinolone compounds
US7691811B2 (en) 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
CA2655128A1 (en) 2006-06-08 2007-12-21 Array Biopharma Inc. Quinoline compounds and methods of use
EP2044939A1 (en) 2006-06-29 2009-04-08 Eisai R&D Management Co., Ltd. Therapeutic agent for liver fibrosis
KR20090109527A (ko) 2006-07-07 2009-10-20 칼립시스, 인코포레이티드 Ｐｄｅ４의 바이사이클릭 헤테로아릴 억제제
WO2008020302A2 (en) 2006-08-17 2008-02-21 Pfizer Products Inc. Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
DE602007012559D1 (de) 2006-09-08 2011-03-31 Univ Johns Hopkins H die schleimhaut
EP2061469B8 (en) 2006-09-11 2014-02-26 Curis, Inc. Quinazoline based egfr inhibitors
US8821943B2 (en) 2006-09-12 2014-09-02 Board Of Regents Of The University Of Nebraska Methods and compositions for targeted delivery of therapeutic agents
US20080096193A1 (en) 2006-10-24 2008-04-24 Charles Robert Bupp Methods and compositions for detecting polynucleotides
CL2007003158A1 (es) 2006-11-02 2008-05-16 Astrazeneca Ab Procedimiento de preparacion de compuestos derivados de quinazolina o sus sales farmaceuticamente aceptables; compuestos intermediarios; procedimiento de preparacion.
TW200829555A (en) 2006-11-10 2008-07-16 Astrazeneca Ab Chemical compounds
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US7915287B2 (en) 2006-12-20 2011-03-29 Amgen Inc. Substituted heterocycles and methods of use
CN100540551C (zh) 2007-02-01 2009-09-16 中国药科大学 喹啉衍生物、其制备方法及其医药用途
CN100540552C (zh) 2007-02-01 2009-09-16 中国药科大学 3-氰基喹啉衍生物、其制备方法及其医药用途
WO2008097976A1 (en) 2007-02-09 2008-08-14 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
CA2676173A1 (en) 2007-02-16 2008-08-28 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
JP2008214323A (ja) 2007-03-08 2008-09-18 Kyowa Hakko Kogyo Co Ltd 皮膚疾患の治療及び／または予防剤
JP5577104B2 (ja) 2007-03-14 2014-08-20 エクセリクシス パテント カンパニー エルエルシー ヘッジホッグ経路の阻害剤
WO2008113161A1 (en) 2007-03-19 2008-09-25 Ulysses Pharmaceutical Products Inc. Phosphate prodrugs of quinazolinyl nitrofurans, methods of obtaining, and use of same
DE102007015169A1 (de) 2007-03-27 2008-10-02 Universität des Saarlandes Campus Saarbrücken 17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen
JP2010523595A (ja) 2007-04-04 2010-07-15 マサチューセッツ インスティテュート オブ テクノロジー ポリ（アミノ酸）ターゲッティング部分
DE102007017654A1 (de) 2007-04-12 2008-10-16 Henkel Ag & Co. Kgaa Bis(hydroxychinolin)-Metallkomplexe als Bleichkatalysatoren
CN101317847B (zh) 2007-06-06 2010-10-13 深圳市瑞谷医药技术有限公司 一种眼用或耳鼻用药物组合物及其用途
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
TW200904817A (en) 2007-06-19 2009-02-01 Astrazeneca Ab Compounds and uses thereof
WO2009014730A1 (en) 2007-07-26 2009-01-29 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
WO2009018092A1 (en) 2007-07-27 2009-02-05 The Board Of Trustees Of The Leland Stanford Junior University Supramolecular functionalization of graphitic nanoparticles for drug delivery
CN101108846B (zh) 2007-08-10 2011-02-09 东南大学 4-芳香氨基喹唑啉衍生物及制备方法和在制药中的应用
US20090062337A1 (en) 2007-08-31 2009-03-05 Wysis Technology Foundation, Inc. Treatment of Microbial Infections
WO2009030224A2 (de) 2007-09-07 2009-03-12 Schebo Biotech Ag Neue chinazolin- verbindungen und ihre verwendung zur therapie von krebserkrankungen
DE102008012435A1 (de) * 2008-02-29 2009-09-03 Schebo Biotech Ag Neue Pharmazeutika, Verfahren zu ihrer Herstellung und ihre Verwendung in der Therapie
TW200922590A (en) * 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety
JP2010540459A (ja) 2007-09-24 2010-12-24 トラガラ ファーマシューティカルズ，インク． Ｃｏｘ‐２阻害薬及びｅｇｆｒ［ｅｒｂｂ１］とｈｅｒ‐２［ｅｒｂｂ２］の二重阻害薬を用いた癌を治療するための併用療法
EP2247579B1 (en) 2008-01-17 2012-04-18 Bayer Pharma Aktiengesellschaft Sulphoximine-substituted quinazoline derivatives as immunomodulators, their preparation and use as medicaments
WO2009094211A1 (en) 2008-01-22 2009-07-30 Concert Pharmaceuticals Inc. Quinazoline compounds and methods of treating cancer
CN102016590A (zh) 2008-02-28 2011-04-13 生命技术公司 荧光偏振hERG试验
CN102046179B (zh) 2008-04-09 2015-01-14 英菲尼提制药公司 脂肪酸酰胺水解酶抑制剂
MX2010012290A (es) 2008-05-14 2011-02-21 Amgen Inc Combinaciones de inhibidores del receptor del factor de crecimiento endotelial vascular e inhibidores del factor de crecimiento de hepatocito para el tratamiento de cancer.
EP2149565A1 (de) 2008-07-24 2010-02-03 Bayer Schering Pharma AG Sulfonsubstituierte Chinazolinderivate als Immunmodulatoren zur Behandlung von enzündlichen und allergischen Erkrankungen
US8211911B2 (en) 2008-08-19 2012-07-03 Guoqing Paul Chen Compounds as kinase inhibitors
TWI580441B (zh) 2008-09-19 2017-05-01 愛爾康研究有限公司 穩定的藥學次微米懸浮液及其形成方法
AU2009303602B2 (en) * 2008-10-14 2012-06-14 Sunshine Lake Pharma Co., Ltd. Compounds and methods of use
WO2010056758A1 (en) 2008-11-12 2010-05-20 Yangbo Feng Quinazoline derivatives as kinase inhibitors
CN101747306B (zh) 2008-11-28 2012-08-29 中国中化股份有限公司 取代醚类化合物及其应用
JP5471063B2 (ja) 2009-02-23 2014-04-16 住友化学株式会社 環状化合物、その金属錯体及び変性金属錯体
TWI461197B (zh) 2009-03-12 2014-11-21 2-mercaptoquinoline-3-carboxamide as a KCNQ2 / 3 modifier
EP2408744A1 (en) 2009-03-18 2012-01-25 Schering Corporation Bicyclic compounds as inhibitors of diacylglycerol acyltransferase
US10952965B2 (en) 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
WO2010151784A2 (en) 2009-06-26 2010-12-29 The General Hospital Corporation Antimicrobial compounds
CA2780111A1 (en) 2009-11-07 2011-05-12 Merck Patent Gmbh Heteroarylaminoquinolines as tgf-beta receptor kinase inhibitors
EP2335686A1 (en) 2009-12-21 2011-06-22 LEK Pharmaceuticals d.d. An aqueous intravenous nanosuspension with reduced adverse effects
DE102010006121B4 (de) 2010-01-29 2022-08-11 Merck Patent Gmbh Materialien für organische Elektrolumineszenzvorrichtungen
DE102010007938A1 (de) 2010-02-12 2011-10-06 Merck Patent Gmbh Elektrolumineszierende Polymere, Verfahren zu ihrer Herstellung sowie ihre Verwendung
WO2011106168A1 (en) 2010-02-24 2011-09-01 Dcam Pharma Inc Purine compounds for treating autoimmune and demyelinating diseases
EP2538929A4 (en) 2010-02-25 2014-07-09 Univ Johns Hopkins DELAYED RELEASE OF THERAPIES IN A PART OF THE EYE
JP5654246B2 (ja) 2010-03-03 2015-01-14 一般社団法人ファルマバレープロジェクト支援機構 キナゾリン化合物を有効成分とする医薬組成物
TWI516264B (zh) 2010-05-06 2016-01-11 臺北醫學大學 芳香醯喹啉化合物
DE102010023949A1 (de) 2010-06-16 2011-12-22 F. Holzer Gmbh In-situ Lecithin-Mikroemulsionsgel-Formulierung
JP5921535B2 (ja) 2010-06-16 2016-05-24 ディナバックス テクノロジーズ コーポレイション Ｔｌｒ７および／またはｔｌｒ９阻害剤を用いる治療の方法
US20120252756A1 (en) 2010-06-25 2012-10-04 Coffey Martin J Pharmaceutical Compositions and Methods for Treating, Controlling, Ameliorating, or Reversing Conditions of the Eye
CA2803890A1 (en) 2010-06-25 2011-12-29 Rutgers, The State University Of New Jersey Antimicrobial agents
SG186855A1 (en) 2010-06-28 2013-02-28 Merck Patent Gmbh 2,4- diaryl - substituted [1,8] naphthyridines as kinase inhibitors for use against cancer
WO2012012627A1 (en) 2010-07-22 2012-01-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of preventing or treating viral infection
EP2598131A1 (fr) 2010-07-29 2013-06-05 Laboratoires Fournier S.A. Composes pour le traitement/la prevention des maladies inflammatoires oculaires
WO2012014114A1 (en) 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited Matrix metalloproteinase inhibitors
WO2012025237A1 (en) 2010-08-27 2012-03-01 Grünenthal GmbH Substituted 2-amino-quinoline-3-carboxamides as kcnq2/3 modulators
WO2012039979A2 (en) 2010-09-10 2012-03-29 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
WO2012040499A2 (en) 2010-09-22 2012-03-29 Surface Logix, Inc. Metabolic inhibitors
SG188642A1 (en) 2010-09-24 2013-05-31 Ranbaxy Lab Ltd Matrix metalloproteinase inhibitors
MX2013003360A (es) 2010-09-24 2013-06-05 Ranbaxy Lab Ltd Inhibidores de metaloproteinasa de matriz.
WO2012038944A1 (en) 2010-09-24 2012-03-29 Ranbaxy Laboratories Limited Matrix metalloproteinase inhibitors
WO2012050985A1 (en) 2010-10-13 2012-04-19 Trustees Of Boston University Inhibitors of late sv40 factor (lsf) as cancer chemotherapeutics
EP2629760A4 (en) 2010-10-22 2014-04-02 Bind Therapeutics Inc THERAPEUTIC NANOPARTICLES CONTAINING COPOLYMERS OF HIGH MOLECULAR WEIGHT
DE102010050570A1 (de) 2010-11-05 2012-05-10 F. Holzer Gmbh Zusammensetzung und Arzneimittel enthaltend ω-3-Fettsäuren sowie einen Inhibitor des NF-κB-Transkriptionsfaktors
WO2012061703A1 (en) 2010-11-05 2012-05-10 The Johns Hopkins University Compositions and methods relating to reduced mucoadhesion
WO2012064898A1 (en) 2010-11-09 2012-05-18 Yuan Chen Singleton inhibitors of sumoylation enzymes and methods for their use
US9657292B2 (en) 2010-11-24 2017-05-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Compositions and methods for treating or preventing lupus
WO2012074980A2 (en) 2010-12-01 2012-06-07 Dara Biosciences, Inc. Methods of treating or preventing autoimmune disorders and liver disorders using indane acetic acid derivatives
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
WO2012088431A1 (en) 2010-12-23 2012-06-28 Ironwood Pharmaceuticals, Inc. Faah inhibitors
WO2012093117A1 (en) 2011-01-03 2012-07-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of ocular inflammatory diseases
US8980909B2 (en) 2011-01-12 2015-03-17 Crystal Biopharmaceutical Llc HDAC inhibiting derivatives of camptothecin
WO2012106534A2 (en) 2011-02-02 2012-08-09 The Regents Of The University Of California Hiv integrase inhibitors
WO2012109363A2 (en) 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
US20120214803A1 (en) 2011-02-18 2012-08-23 Vifor (International) Ag Novel Sulfonaminoquinoline Hepcidin Antagonists
CA2826773C (en) 2011-02-24 2019-07-16 Emory University Jab1 blocking compositions for ossification and methods related thereto
EP2688890B1 (en) 2011-03-22 2017-08-30 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
WO2012135416A1 (en) 2011-03-29 2012-10-04 Trana Discovery, Inc. Screening methods for identifying specific staphylococcus aureus inhibitors
EP2697195A1 (en) 2011-04-14 2014-02-19 Allergan, Inc. Phenyl bicyclic methyl azetidine derivatives as sphingosine-1 phosphate receptors modulators
US8507686B2 (en) 2011-04-14 2013-08-13 Allergan, Inc. Substituted bicyclic methyl azetidines as sphingosine-1 phosphate receptors modulators
WO2012145236A1 (en) 2011-04-18 2012-10-26 Allergan, Inc. Substituted bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators
EP2701742A4 (en) 2011-04-26 2015-03-18 Genentech Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF AUTOIMMUNE DISEASES
US8835410B2 (en) 2011-05-10 2014-09-16 Bodor Laboratories, Inc. Treatment of eyelid dermatitis
CA2835343A1 (en) 2011-05-12 2012-11-15 Foresight Biotherapeutics, Inc. Stable povidone-iodine compositions with steroids or non-steroidal anti-inflammatories
WO2012158435A1 (en) 2011-05-17 2012-11-22 Han-Jie Zhou Compositions and methods for jamm protein inhibition
WO2012162698A1 (en) 2011-05-26 2012-11-29 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the treatment of immune disorders
SG195200A1 (en) 2011-06-29 2013-12-30 Otsuka Pharma Co Ltd Quinazolines as therapeutic compounds and related methods of use
WO2013013614A1 (zh) 2011-07-28 2013-01-31 南京英派药业有限公司 4-(3-杂芳基芳基氨基)喹唑啉和1-(3-杂芳基芳基氨基)异喹啉作为Hedgehog通路抑制剂及其应用
JP5753027B2 (ja) 2011-08-22 2015-07-22 ユー・ディー・シー アイルランド リミテッド 有機電界発光素子、化合物、並びに該素子を用いた発光装置、表示装置及び照明装置
TW202023575A (zh) 2011-09-16 2020-07-01 美商遠景生物製藥股份有限公司 安定之普維酮—碘組成物
WO2013061269A1 (en) 2011-10-26 2013-05-02 Micro Labs Limited Combinations of loteprednol and olopatadine for the treatment of ocular allergies
TWI480042B (zh) 2011-11-03 2015-04-11 Taiwan Liposome Co Ltd 疏水性喜樹鹼衍生物之醫藥組合物
WO2013065028A1 (en) 2011-11-04 2013-05-10 Micro Labs Limited Fixed dose combination containing azithromycin and loteprednol for treatment of ocular infections
US20130116279A1 (en) 2011-11-07 2013-05-09 Kalypsys, Inc. Bicyclic heteroaryl inhibitors of pde4
US9458131B2 (en) 2011-11-08 2016-10-04 Emory University Compounds and compositions used to epigenetically transform cells and methods related thereto
CN103102345B (zh) 2011-11-14 2015-06-03 广东东阳光药业有限公司 氨基喹唑啉类衍生物及其盐和使用方法
TWI577671B (zh) 2011-11-14 2017-04-11 Sunshine Lake Pharma Co Ltd Aminoquinazoline derivatives and salts thereof and methods of use thereof
CN103102342B (zh) 2011-11-14 2014-10-29 广东东阳光药业有限公司 氨基喹唑啉类衍生物及其盐和使用方法
US9328138B2 (en) 2011-11-15 2016-05-03 Msd Italia S.R.L. HCV NS3 protease inhibitors
CN104105507B (zh) 2011-12-14 2020-03-24 约翰霍普金斯大学 增强粘膜渗透或减少炎症的纳米粒子
CN103183674B (zh) 2011-12-31 2017-09-12 江苏先声药业有限公司 一类稠杂环衍生物及其应用
WO2013118071A1 (en) 2012-02-09 2013-08-15 Glenmark Pharmaceuticals S.A. BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
US9458185B2 (en) 2012-02-10 2016-10-04 The Regents Of The University Of California First row metal-based catalysts for hydosilylation
CN103304572A (zh) 2012-03-09 2013-09-18 上海医药集团股份有限公司 一类3-氰基喹啉类化合物及其药用组合物和应用
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
KR20150006869A (ko) 2012-05-03 2015-01-19 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
ES3055223T3 (en) 2012-05-03 2026-02-10 Alcon Inc Pharmaceutical nanoparticles showing improved mucosal transport
KR102140989B1 (ko) 2012-05-03 2020-08-04 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
AU2013269270A1 (en) 2012-06-01 2015-01-15 Oxalys Pharmaceuticals Chemical suppressors of neurotoxicity in synucleinopathic diseases
JP2015521603A (ja) 2012-06-15 2015-07-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ 脳癌の新規治療薬
CN107459508A (zh) 2012-07-20 2017-12-12 克里弗生物科学公司 作为p97复合物的抑制剂的稠合嘧啶
CN103804292A (zh) 2012-11-05 2014-05-21 江苏唐果医药科技有限公司 Hdm2和hdmx双重抑制剂3－腈基喹啉衍生物及其制备方法与应用
WO2014074517A1 (en) 2012-11-08 2014-05-15 Emory University Cellular compositions used to restore stem cell or progenitor cell function and methods related thereto
WO2014074848A1 (en) 2012-11-08 2014-05-15 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions and their use as pkm2 modulators
WO2014074926A1 (en) 2012-11-09 2014-05-15 Rutgers, The State University Of New Jersey Therapeutic hydroxyquinolones
KR102051910B1 (ko) 2012-11-30 2019-12-09 에스에프씨주식회사 중수소 치환된 유기금속 착물 및 이를 포함하는 유기 발광 소자
WO2014086284A1 (zh) 2012-12-04 2014-06-12 上海医药集团股份有限公司 一类氘代3-氰基喹啉类化合物、其药用组合物、制备方法及其用途
JP6556630B2 (ja) 2012-12-21 2019-08-07 メルク パテント ゲーエムベーハー 金属錯体
KR102084421B1 (ko) 2013-02-15 2020-03-05 에스에프씨주식회사 신규한 유기 화합물 및 이를 포함하는 유기 발광 소자
BR112015020139A2 (pt) 2013-02-20 2017-07-18 Kala Pharmaceuticals Inc compostos terapêuticos e usos dos mesmos
KR102118013B1 (ko) 2013-02-22 2020-06-05 에스에프씨주식회사 신규한 유기 화합물 및 이를 포함하는 유기 발광 소자
CN105308031B (zh) 2013-03-04 2017-10-13 健康科学北方研究所 喹啉磺酰基衍生物及其用途
WO2014141057A2 (en) 2013-03-12 2014-09-18 Mahesh Kandula Compositions and methods for the treatment of cancer
WO2014141110A2 (en) 2013-03-14 2014-09-18 Curadev Pharma Pvt. Ltd. Aminonitriles as kynurenine pathway inhibitors
CN105407894A (zh) 2013-03-14 2016-03-16 康威基内有限公司 用于抑制含布罗莫结构域的蛋白质的方法和组合物
SG11201506385WA (en) 2013-03-18 2015-10-29 Genoscience Pharma Quinolines derivatives as novel anticancer agents
EP2994142A4 (en) 2013-05-08 2017-03-29 Colorado Seminary, Which Owns and Operates The University of Denver Antibiotic and anti-parasitic agents that modulate class ii fructose 1,6-bisphosphate aldolase
EP2996691A1 (en) 2013-05-16 2016-03-23 The U.S.A. as represented by the Secretary, Department of Health and Human Services Compounds for inhibiting drug-resistant strains of hiv-1 integrase
EP3057947B1 (de) 2013-10-14 2018-10-17 Merck Patent GmbH Materialien für elektronische vorrichtungen
KR20160099084A (ko) * 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. 치료 화합물의 결정질 형태 및 그의 용도

Also Published As

Publication number Publication date
MX355330B (es) 2018-04-16
EP3062618A4 (en) 2017-07-12
MX2016005668A (es) 2016-10-28
EP3062618A1 (en) 2016-09-07
US9790232B2 (en) 2017-10-17
WO2015066482A1 (en) 2015-05-07
CN106061261A (zh) 2016-10-26
CN106061261B (zh) 2018-04-24
US9458169B2 (en) 2016-10-04
US20190077810A1 (en) 2019-03-14
EP3062618B1 (en) 2020-02-05
KR20160099084A (ko) 2016-08-19
JP2019038825A (ja) 2019-03-14
US20160115176A1 (en) 2016-04-28
CN108530458A (zh) 2018-09-14
JP2016535100A (ja) 2016-11-10
US10160765B2 (en) 2018-12-25
JP6426194B2 (ja) 2018-11-21
US11713323B2 (en) 2023-08-01
US20200216459A1 (en) 2020-07-09
US20150125535A1 (en) 2015-05-07
AU2014342042A1 (en) 2016-05-12
AU2014342042B2 (en) 2017-08-17
US20180009824A1 (en) 2018-01-11
CA2928658A1 (en) 2015-05-07
US10618906B2 (en) 2020-04-14
US20210355133A1 (en) 2021-11-18
US10975090B2 (en) 2021-04-13

Similar Documents

Publication Publication Date Title
NZ719185A (en) Crystalline forms of therapeutic compounds and uses thereof
GEP201706780B (en) Substituted 2-aza-bicyclo [2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
MX360598B (es) Inhibidores de bromodominio de benzo [c] isoxazoloazepina y sus usos.
TN2016000238A1 (en) Tricyclic compounds as anticancer agents.
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
UA115558C2 (uk) Алкілпіримідинові похідні для лікування вірусних інфекцій та подальших захворювань
IN2015DN01156A (enExample)
MX2016002368A (es) Compuestos de sulfonamida heterociclica sustituida utiles como moduladores del canal del receptor de potencial transitorio a1 (trpa1).
NZ700928A (en) Dna-pk inhibitors
MX2015009037A (es) Enjuague nasal con miel.
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
MX2015010128A (es) Derivados de piridazinona macrociclicos.
CA2818187C (en) Bromodomain inhibitors and uses thereof
WO2014152029A3 (en) Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors
MX370017B (es) Compuestos de [1,2,4]triazolo[1,5-c]quinazolin-5-amina heterobiciclo-sustituidos con propiedades antagonistas para a2a.
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
EA201990529A1 (ru) Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
HK1217092A1 (zh) 治疗性化合物及其用途
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists
IN2012DN00239A (enExample)
MX2015012720A (es) Sales basicas de adicion de nitroxolina y usos de las mismas.
MX366829B (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
HK1228278A1 (en) Crystalline forms of therapeutic compounds and uses thereof

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 OCT 2019 BY DENNEMEYER + CO

Effective date: 20180927

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 OCT 2020 BY DENNEMEYER + CO.

Effective date: 20190923

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 OCT 2021 BY DENNEMEYER + CO.

Effective date: 20201019

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 OCT 2022 BY DENNEMEYER + CO.

Effective date: 20211018

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 OCT 2023 BY DENNEMEYER + CO. S.A.R.L.

Effective date: 20221024

LAPS Patent lapsed